All lobbying filings

AVENUE SOLUTIONS

Lobbying for OMEROS CORPORATION · Biopharmaceutical company

Filing 1st Quarter - Termination

1st Quarter (Jan 1 - Mar 31) 2025 · Washington · Senate · $80,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 2

S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 2

Budget/Appropriations

Issues related to the FDA and treatment for rare disease

Health Issues

Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.